FDA approves Foundayo for obesity treatment
The Saudi Food and Drug Authority has approved the registration of the medication "Fondaio" for weight loss in adults suffering from obesity or excess weight combined with related medical conditions. It is taken orally once daily and works by activating glucagon-like peptide receptors to regulate appetite and blood sugar levels, thereby reducing food cravings and aiding in weight loss. Clinical studies have shown that an effective dose of 36 mg results in an average weight reduction of 11.2% among obese individuals without diabetes and 9.6% among those with diabetes over a 72-week period. Side effects observed include gastrointestinal disturbances, hair loss, and fatigue, which were generally mild to moderate and tended to resolve over time. It is emphasized that the medication should be used under medical supervision, especially for patients with a family or personal history of thyroid tumors. This approval aims to expand obesity treatment options and improve healthcare quality in line with Saudi Vision 2030.
Notice: This Is an AI-Generated Summary
Comments (0)